Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ipsen S.A. ADR (IPSEY)

Ipsen S.A. ADR (IPSEY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 7,732,603
  • Shares Outstanding, K 335,180
  • Annual Sales, $ 3,016 M
  • Annual Income, $ -56,780 K
  • 60-Month Beta 1.26
  • Price/Sales N/A
  • Price/Cash Flow 9.05
  • Price/Book 3.71
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/13/20
  • Annual Dividend & Yield 0.20 (0.87%)
  • Most Recent Dividend 0.194 on 06/03/20
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.5000 +12.20%
on 06/24/20
23.0700 -0.30%
on 07/13/20
+2.7100 (+13.36%)
since 06/11/20
3-Month
14.4400 +59.28%
on 04/15/20
23.0700 -0.30%
on 07/13/20
+7.3500 (+46.96%)
since 04/14/20
52-Week
9.1000 +152.75%
on 03/18/20
32.3700 -28.95%
on 07/22/19
-8.7500 (-27.56%)
since 07/12/19

Most Recent Stories

More News
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX(R)) Plus Atezolizumab in Metastatic Non-Small Cell Lung Cancer and Metastatic Castration-Resistant Prostate Cancer

--Participation will provide Ipsen access to the respective study results to support potential future regulatory submissions in its territories

IPN : 34.71 (-0.54%)
IPSEY : 23.0000 (-0.30%)
Ipsen presents Phase I/II clinical data evaluating liposomal irinotecan (Onivyde(R)) as an investigational first-line combination treatment for metastatic pancreatic cancer at the ESMO World Congress on Gastrointestinal Cancer

--Ipsen has been granted Fast Track Designation by the FDA for investigational liposomal irinotecan + 5-FU/LV + OX (NALIRIFOX) for the first-line treatment of patients with metastatic pancreatic cancer...

IPN : 34.71 (-0.54%)
IPSEY : 23.0000 (-0.30%)
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE(R)) as a First-Line Combination Treatment for Metastatic Pancreatic Cancer

Regulatory News:

IPN : 34.71 (-0.54%)
IPSEY : 23.0000 (-0.30%)
Photocure Enters into Final Agreement to Regain Worldwide Rights of Hexvix

, /PRNewswire/ --

PHCUF : 7.1500 (-6.11%)
PHO : 37.40 (+2.44%)
IPN : 34.71 (-0.54%)
IPSEY : 23.0000 (-0.30%)
Ipsen Initiates a Share Buyback Program to Cover Its Share Allocation Plan

Regulatory News:

IPN : 34.71 (-0.54%)
IPSEY : 23.0000 (-0.30%)
Ipsen Demonstrates Continued Commitment to Rare Diseases With Eight Abstracts Accepted at ENDO 2020 Published in the Journal of the Endocrine Society

--The Natural History Study (NHS) is the first protocol-specified, longitudinal evaluation of FOP disease progression

IPN : 34.71 (-0.54%)
IPSEY : 23.0000 (-0.30%)
Ipsen Appoints David Loew as Chief Executive Officer

Regulatory News:

IPN : 34.71 (-0.54%)
IPSEY : 23.0000 (-0.30%)
Acute Kidney Injury Treatment Market Present And Upcoming Trends With COVID 19 Impact Study | Novartis AG, Pfizer Inc, Ipsen SA

MarketResearch.Biz published a new industry research report “Acute Kidney Injury Treatment Market” in its database. This is a latest report, including the present COVID-19 impact and future effect on...

CNAT : 0.5560 (+0.18%)
IPSEY : 23.0000 (-0.30%)
MRK : 78.25 (+1.16%)
NVS : 87.47 (+1.61%)
PFE : 35.23 (+0.06%)
TEVA : 11.72 (+1.30%)
VRX.TO : 30.80 (-3.33%)
Ipsen: New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom Recurrence

Regulatory News:

IPN : 34.71 (-0.54%)
IPSEY : 23.0000 (-0.30%)
Ipsen Announces Publication of First Matching-Adjusted Indirect Comparison of Cabometyx(R) (cabozantinib) Versus regorafenib in Advanced Hepatocellular Carcinoma in Advances in Therapy

Regulatory News:

IPN : 34.71 (-0.54%)
IPSEY : 23.0000 (-0.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade IPSEY with:

Key Turning Points

2nd Resistance Point 23.4300
1st Resistance Point 23.2500
Last Price 23.0000
1st Support Level 22.7100
2nd Support Level 22.3500

See More

52-Week High 32.3700
Fibonacci 61.8% 23.4809
Last Price 23.0000
Fibonacci 50% 20.7350
Fibonacci 38.2% 17.9891
52-Week Low 9.1000

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar